drugset / Trial / NCT06219733

Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

NCT06219733

Phase 2 Withdrawn MedPacto, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy

Timeline

Start
2021-06-01
Primary completion
2022-05-23
Completion
2022-05-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Imatinib Small molecule 400 mg Oral
Subject Vactosertib Small molecule 200 mg Oral

Indications